journal article·2022-07-01Open access

A parallelized, perfused 3D triculture model of leukemia for in vitro drug testing of chemotherapeutics

Sabrina Zippel, Nadine Dilger, Chandralekha Chatterjee, Annamarija Raic, Gerald Brenner-Weiß, Patrik Schadzek, Bastian E Rapp, Cornelia Lee-Thedieck

Biofabrication· Volume 14· Issue 3

Abstract

Abstract Leukemia patients undergo chemotherapy to combat the leukemic cells (LCs) in the bone marrow. During therapy not only the LCs, but also the blood-producing hematopoietic stem and progenitor cells (HSPCs) may be destroyed. Chemotherapeutics targeting only the LCs are urgently needed to overcome this problem and minimize life-threatening side-effects. Predictive in vitro drug testing systems allowing simultaneous comparison of various experimental settings would enhance the efficiency of drug development. Here, we present a three-dimensional (3D) human leukemic bone marrow model perfused using a magnetic, parallelized culture system to ensure media exchange. Chemotherapeutic treatment of the acute myeloid leukemia cell line KG-1a in 3D magnetic hydrogels seeded with mesenchymal stem/stromal cells (MSCs) revealed a greater resistance of KG-1a compared to 2D culture. In 3D tricultures with HSPCs, MSCs and KG-1a, imitating leukemic bone marrow, HSPC proliferation decreased while KG-1a cells remained unaffected post treatment. Non-invasive metabolic profiling enabled continuous monitoring of the system. Our results highlight the importance of using biomimetic 3D platforms with proper media exchange and co-cultures for creating in vivo-like conditions to enable in vitro drug testing. This system is a step towards drug testing in biomimetic, parallelized in vitro approaches, facilitating the discovery of new anti-leukemic drugs.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Hematopoietic Stem Cell Transplantation · Acute Myeloid Leukemia Research · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (68)

Show source-provided references
1. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell10.2353/ajpath.2006.060312 ↗
3. Hematopoietic stem cell: self-renewal versus differentiation10.1002/wsbm.86 ↗
4. Acute myeloid leukemia10.1056/NEJMra1406184 ↗
5. What you need to know about leukemia
6. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression10.3109/07357909809115775 ↗
7. Childress · 2015 · p 2210.1007/978-3-319-21702-4_1 ↗
8. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche10.1038/nature09262 ↗
9. Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment10.1182/blood-2005-06-2211 ↗
10. Normal and leukemic stem cell niches: insights and therapeutic opportunities10.1016/j.stem.2015.02.014 ↗
11. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers10.1038/leu.2008.299 ↗
12. Regulation of hematopoietic and leukemic stem cells by the immune system10.1038/cdd.2014.89 ↗
13. The third dimension bridges the gap between cell culture and live tissue10.1038/nrm2236 ↗
14. A practical guide to hydrogels for cell culture10.1038/nmeth.3839 ↗
15. 3D cell culture systems: advantages and applications10.1002/jcp.24683 ↗
16. Biomimetic macroporous PEG hydrogels as 3D scaffolds for the multiplication of human hematopoietic stem and progenitor cells10.1016/j.biomaterials.2013.10.038 ↗
17. Magnetic macroporous hydrogels as a novel approach for perfused stem cell culture in 3D scaffolds via contactless motion control10.1002/adhm.201701403 ↗
18. 3D models of the hematopoietic stem cell niche under steady-state and active conditions10.1038/s41598-017-04808-0 ↗
19. A three-dimensional ex vivo tri-culture model mimics cell-cell interactions between acute myeloid leukemia and the vascular niche10.3324/haematol.2016.157883 ↗
20. Versatile humanized niche model enables study of normal and malignant human hematopoiesis10.1172/JCI89364 ↗
21. Mimicking the acute myeloid leukemia niche for molecular study and drug screening10.1089/ten.tec.2016.0404 ↗
22. Three dimensional spheroid cell culture for nanoparticle safety testing10.1016/j.jbiotec.2015.01.001 ↗
23. Deconstructing the third dimension: how 3D culture microenvironments alter cellular cues10.1242/jcs.079509 ↗
24. Culturing patient-derived malignant hematopoietic stem cells in engineered and fully humanized 3D niches10.1073/pnas.2114227118 ↗
25. Ex vivo expansion of hematopoietic stem cells derived from umbilical cord blood in rotating wall vessel10.1016/j.jbiotec.2006.01.020 ↗
26. Stirred culture of peripheral and cord blood hematopoietic cells offers advantages over traditional static systems for clinically relevant applications10.1002/(sici)1097-0290(19980905)59:5<534::aid-bit2>3.0.co;2-b ↗
27. The hollow fiber bioreactor as a stroma-supported, serum-free ex vivo expansion platform for human umbilical cord blood cells10.1002/biot.201300320 ↗
28. Metabolic profiling of hematopoietic stem and progenitor cells during proliferation and differentiation into red blood cells10.1016/j.nbt.2015.05.002 ↗
29. Introduction to the molecular basis of cancer metabolism and the Warburg effect10.1007/s11033-015-3857-y ↗
30. Targeting the adenosinergic axis in chronic lymphocytic Leukemia: a way to disrupt the tumor niche?10.3390/ijms19041167 ↗
31. Ectonucleotidases in blood malignancies: a tale of surface markers and therapeutic targets10.3389/fimmu.2019.02301 ↗
32. Caspase mediated enhanced apoptotic action of cyclophosphamide- and resveratrol-treated MCF-7 cells10.1254/jphs.08173FP ↗
33. Inhibitory effect of imatinib on normal progenitor cells in vitro10.1182/blood-2003-05-1535 ↗
34. Rödling · 2014 · p 12110.1007/7651_2014_84 ↗
35. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug10.1038/nrd839 ↗
36. Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling10.1038/srep27378 ↗
37. Mechanistic Models for Myelosuppression10.1023/A:1023573429626 ↗
38. Clinical pharmacokinetics of cyclophosphamide10.2165/00003088-200544110-00003 ↗
39. The leukemic stem cell niche: current concepts and therapeutic opportunities10.1182/blood-2009-01-202606 ↗
40. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells10.1016/j.bbrc.2010.03.138 ↗
41. Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia10.1038/sj.leu.2404358 ↗
42. Retinoic acid induction of CD38 antigen expression on normal and leukemic human myeloid cells: relationship with cell differentiation10.1080/1042819031000060564 ↗
43. Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors10.1038/leu.2013.202 ↗
44. Effects of phorbol ester on translocation and down-regulation of protein kinase C and phosphorylation of endogenous proteins in human acute myeloid leukemia cell line KG-1 and its phorbol ester-resistant subline KG-1a
45. The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations10.1038/leu.2011.238 ↗
46. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling10.1038/nm.4210 ↗
47. Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model10.1038/leu.2011.210 ↗
48. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin10.1038/sj.leu.2403899 ↗
49. Epigenetic perturbations by Arg882-mutated DNMT3A potentiate aberrant stem cell gene-expression program and acute leukemia development10.1016/j.ccell.2016.05.008 ↗
50. DNMT3A mutation-induced CDK1 overexpression promotes leukemogenesis by modulating the interaction between EZH2 and DNMT3A10.3390/biom11060781 ↗
51. FLT3 mutations in acute myeloid leukemia cell lines10.1038/sj.leu.2402740 ↗
52. Modulation of FLT3 through decitabine-activated C/EBPa-PU.1 signal pathway in FLT3-ITD positive cells10.1016/j.cellsig.2019.109409 ↗
53. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia10.1038/leu.2014.231 ↗
54. Myeloid toxicity of cancer treatment10.6004/jadpro.2012.3.4.2 ↗
55. In vitro biomimetic engineering of a human hematopoietic niche with functional properties10.1073/pnas.1805440115 ↗
56. Development and molecular characterization of polymeric micro-nanofibrous scaffold of a defined 3D niche for in vitro chemosensitivity analysis against acute myeloid leukemia cells10.2147/IJN.S80397 ↗
57. A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells10.3109/10428194.2013.793323 ↗
58. 3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expression10.3892/etm.2019.7153 ↗
59. Three dimensional de novo micro bone marrow and its versatile application in drug screening and regenerative medicine10.1177/1535370215594583 ↗
60. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia10.1371/journal.pone.0107587 ↗
61. In vitro modeling of tissue-specific 3D microenvironments and possible application to pediatric cancer research10.14205/2309-3021.2014.02.01.5 ↗
62. Syntheses and biological evaluation of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib10.1016/j.bmcl.2016.01.068 ↗
63. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-110.18632/oncotarget.11063 ↗
64. Moving myeloid leukemia drug discovery into the third dimension10.3389/fped.2019.00314 ↗
65. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells10.1126/scitranslmed.3000349 ↗
66. Bone-marrow haematopoietic-stem-cell niches10.1038/nri1779 ↗
67. Extracellular adenosine sensing—a metabolic cell death priming mechanism downstream of p5310.1016/j.molcel.2013.03.016 ↗
68. Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine10.1186/s13287-018-0936-8 ↗